CN110740757B - 新型psma-结合剂及其用途 - Google Patents

新型psma-结合剂及其用途 Download PDF

Info

Publication number
CN110740757B
CN110740757B CN201880034324.3A CN201880034324A CN110740757B CN 110740757 B CN110740757 B CN 110740757B CN 201880034324 A CN201880034324 A CN 201880034324A CN 110740757 B CN110740757 B CN 110740757B
Authority
CN
China
Prior art keywords
psma
alb
acid
compound
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880034324.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110740757A (zh
Inventor
M·贝内索瓦
C·缪勒
C·乌姆里希特
R·希伯里
K·哲尔诺舍科夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherrer Paul Institut
Isotope Technology Munich
Original Assignee
Scherrer Paul Institut
Isotope Technology Munich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/000717 external-priority patent/WO2018233798A1/en
Application filed by Scherrer Paul Institut, Isotope Technology Munich filed Critical Scherrer Paul Institut
Publication of CN110740757A publication Critical patent/CN110740757A/zh
Application granted granted Critical
Publication of CN110740757B publication Critical patent/CN110740757B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
    • A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880034324.3A 2017-05-24 2018-05-24 新型psma-结合剂及其用途 Active CN110740757B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17000891 2017-05-24
EP17000891.6 2017-05-24
PCT/EP2017/000717 WO2018233798A1 (en) 2017-06-20 2017-06-20 Novel psma-binding agents and uses thereof
EPPCT/EP2017/000717 2017-06-20
PCT/EP2018/063734 WO2018215627A1 (en) 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof

Publications (2)

Publication Number Publication Date
CN110740757A CN110740757A (zh) 2020-01-31
CN110740757B true CN110740757B (zh) 2023-04-04

Family

ID=62200468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034324.3A Active CN110740757B (zh) 2017-05-24 2018-05-24 新型psma-结合剂及其用途

Country Status (9)

Country Link
US (1) US11629201B2 (https=)
EP (1) EP3630204A1 (https=)
JP (1) JP7340459B2 (https=)
KR (1) KR102843240B1 (https=)
CN (1) CN110740757B (https=)
AU (1) AU2018274184B2 (https=)
CA (1) CA3060143A1 (https=)
WO (1) WO2018215627A1 (https=)
ZA (1) ZA201906832B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US12228480B2 (en) * 2018-11-30 2025-02-18 Revvity Health Sciences, Inc. Biological sample preparation using electric fields
CA3127188A1 (en) 2019-01-17 2020-07-23 Case Western Reserve University Peptide pet/spect probes specific to oncoproteins in tumor extracellularmatrix
WO2020210909A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
US20220313600A1 (en) * 2019-05-24 2022-10-06 Clarity Pharmaceuticals Limited Formulations of psma imaging agents
CN114401947B (zh) 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
TWI803688B (zh) * 2019-08-26 2023-06-01 行政院原子能委員會核能研究所 一種psma靶向放射診療藥物備製方法
KR102269315B1 (ko) * 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
KR20230154183A (ko) * 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
JP2024520180A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
JP2024544870A (ja) * 2021-11-10 2024-12-05 スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用
EP4436979A1 (en) * 2021-11-26 2024-10-02 Full-Life Technologies HK Limited Cleavable radioligands for targeting cell surface receptors and uses thereof
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
JP2025530229A (ja) * 2022-09-07 2025-09-11 ３ベー ファーマシューティカルズ ゲーエムベーハー 前立腺特異的膜抗原（ｐｓｍａ）リガンドおよびその使用
CN119855612A (zh) * 2022-09-09 2025-04-18 同宜医药（苏州）有限公司 放射性核素偶联药物及其药物组合物和应用
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
AU2023347470A1 (en) 2022-09-23 2025-04-10 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
AU2024282453A1 (en) * 2023-05-31 2025-12-04 Full-Life Technologies Uk Limited Conjugates and uses thereof
WO2024245421A1 (en) * 2023-05-31 2024-12-05 Full-Life Technologies Hk Limited Radioligands for targeting cell surface receptors and uses thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025088147A1 (en) * 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9687572B2 (en) * 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
WO2013022797A1 (en) 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
AU2012296937B2 (en) 2011-08-17 2017-10-12 Merck & Cie Folate conjugates of albumin-binding entities
SI2970345T1 (sl) 2013-03-15 2019-11-29 Cancer Targeted Tech Llc 18F-označena PSMA-ciljana sredstva za pet slikanje
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112019002560B1 (pt) 2016-08-10 2022-08-16 Cancer Targeted Technology Llc Composto, composição farmacêutica, seus usos e método de preparação do mesmo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice;Cindy J. Choy et al;《Theranostics》;20170427;第7卷(第7期);第1928-1939页 *
Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64Cu-Based PET Imaging;Christoph A. Umbricht et al;《Mol. Pharmaceutics》;20181030;第15卷;第5556-5564页 *
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer;James M. Kelly et al;《THE JOURNAL OF NUCLEAR MEDICINE》;20170427;第58卷(第9期);第1442-1449页 *
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy;Christoph A. Umbricht et al;《Mol. Pharmaceutics》;20180423;第15卷;第2297-2306页 *
以核素标记前列腺特异性膜抗原小分子抑制剂为探针的前列腺癌分子影像研究进展;胡四龙 等;《肿瘤影像学》;20151231;第24卷(第3期);第161-167页 *

Also Published As

Publication number Publication date
JP2020520902A (ja) 2020-07-16
JP7340459B2 (ja) 2023-09-07
RU2019141963A3 (https=) 2021-09-22
ZA201906832B (en) 2024-02-28
US11629201B2 (en) 2023-04-18
CN110740757A (zh) 2020-01-31
WO2018215627A1 (en) 2018-11-29
RU2019141963A (ru) 2021-06-24
AU2018274184B2 (en) 2024-06-13
AU2018274184A1 (en) 2019-11-07
CA3060143A1 (en) 2018-11-29
KR20200009091A (ko) 2020-01-29
KR102843240B1 (ko) 2025-08-05
US20210009715A1 (en) 2021-01-14
EP3630204A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
CN110740757B (zh) 新型psma-结合剂及其用途
JP7059372B2 (ja) デュアルモードの放射性トレーサーおよび療法剤
JP7729441B2 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、ｉｎ ｖｉｔｒｏ法、及びその化合物
CN113149921B (zh) 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
Capasso et al. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy
Grus et al. Squaric acid-based radiopharmaceuticals for tumor imaging and therapy
CZ20032597A3 (cs) Analogy kyseliny askorbové pro metaloradiofarmaceutika
Schmidtke et al. Gallium complexation, stability, and bioconjugation of 1, 4, 7-triazacyclononane derived chelators with azaheterocyclic arms
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
Ling et al. The radiopharmaceutical chemistry of the radioisotopes of copper
WO2018233798A1 (en) Novel psma-binding agents and uses thereof
KR20250006177A (ko) 테라노스틱 플루오르화규소 헤테로방향족 시스템 및 이의 방법
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
RU2831681C2 (ru) Новые связывающие опухолевый антиген агенты и их применение
HK40054611A (en) Novel tumor antigen binding agents and uses thereof
JP2025532619A (ja) イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン２受容体結合分子
Trencsényi et al. Comparative preclinical evaluation of 68Ga-NODAGA
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
EA052134B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant